[
    {
        "doc_id": "doc_0",
        "chunk_num": 0,
        "chunk_text": "This guideline provides evidence-informed guidance on the use of lower-sodium salt substitutes (LSSS).  The recommendation in this guideline can be used by policy-makers, programme managers, health professionals and other stakeholders in their efforts to promote reduction of sodium intake and reduce the risk of hypertension and related noncommunicable diseases through a range of public health policy actions and intervention programmes.  The recommendation in this guideline should be used in"
    },
    {
        "doc_id": "doc_0",
        "chunk_num": 1,
        "chunk_text": "conjunction with other WHO guidance on healthy diets. Nutrition Guidance Expert Advisory Group (NUGAG): Diet and health"
    },
    {
        "doc_id": "doc_1",
        "chunk_num": 0,
        "chunk_text": "This practical guideline establishes definitions for \u201ccontact\u201d, \u201ccontact  person\u201d, \u201ccontact tracing\u201d and other associated concepts. It allows for  improvement of contact tracing strategies and provides recommendations  attempting to answer some, though not all, questions that arose during the 2019  coronavirus pandemic and other outbreaks. The use of this guideline begins once  people have been diagnosed and the potential for transmission exists. It is  not, however, intended to assist with case"
    },
    {
        "doc_id": "doc_1",
        "chunk_num": 1,
        "chunk_text": "investigation.\u202fThe guideline  empowers health workers, governments, and public health officials with the  tools to implement effective contact tracing strategies.\u00a0 \u00a0 WHO releases first disease-agnostic guideline on contact tracing Video \"Infectious diseases: WHO guideline on contact tracing\""
    },
    {
        "doc_id": "doc_2",
        "chunk_num": 0,
        "chunk_text": "Rapid diagnosis of Ebola and Marburg virus disease is critical to provide timely and appropriate care and stop transmission. These diseases can be difficult to clinically distinguish from other infectious diseases such as malaria, and countermeasures, including vaccines and therapeutics, are available specifically for some species of orthoebolaviruses and orthomarburgviruses, meaning that laboratory confirmation is very important. Handling of samples from patients with suspected Ebola or Marburg"
    },
    {
        "doc_id": "doc_2",
        "chunk_num": 1,
        "chunk_text": "virus disease requires appropriate biosafety measures.\u00a0 The purpose of this interim guidance is to provide recommendations and operational considerations regarding the diagnosis of Ebola or Marburg virus disease to laboratory personnel, clinicians, health workers, public health officials and other stakeholders involved in the diagnosis and care of individuals with suspected or confirmed Ebola or Marburg virus disease. \u00a0 Health topic: Marburg virus disease"
    },
    {
        "doc_id": "doc_3",
        "chunk_num": 0,
        "chunk_text": "Pneumonia and diarrhoea account for 23% of under-five mortality and were responsible for an estimated 1.17 million deaths in children under five globally. Furthermore, pneumonia and diarrhoea were responsible for 18% of mortality in children 5\u20139 years of age, resulting in an estimated 86 000 preventable deaths globally in 2021. Existing World Health Organization (WHO) guidance on the clinical management of pneumonia and diarrhoea has mainly focused on children less than 5 years of age. WHO had"
    },
    {
        "doc_id": "doc_3",
        "chunk_num": 1,
        "chunk_text": "not developed clinical guidance on the management of these conditions in children 5\u20139 years of age, which is a gap being addressed in response to calls from national policy- and decision-makers.  The goal of the guideline is to develop, update and consolidate recommendations on the management of pneumonia and diarrhoea in order to inform, revise or update the development of clinical protocols for the management of pneumonia and diarrhoea in children up to 10 years of age.  This guideline aims to"
    },
    {
        "doc_id": "doc_3",
        "chunk_num": 2,
        "chunk_text": "help WHO Member States and their partners make evidence-informed decisions on the appropriate actions in their efforts to address common childhood illnesses, including pneumonia and diarrhoea.   The main changes from previous recommendations involve giving greater scope for pneumonia treatment at the community level, using a specific set of signs and symptoms to diagnose hypoxaemia when pulse oximetry is not available, and a new dose for zinc supplementation. The recommendations are intended for"
    },
    {
        "doc_id": "doc_3",
        "chunk_num": 3,
        "chunk_text": "a wide audience involved in the management of pneumonia and diarrhoea in children."
    },
    {
        "doc_id": "doc_4",
        "chunk_num": 0,
        "chunk_text": "The World Health Organization (WHO) has developed guidelines for the management of infants aged 0-59 days with serious bacterial infections (sepsis, meningitis, and pneumonia) in hospital and also outside hospital if referral is not possible.  The guidelines now include recommendations on diagnosis as well as first line empiric antibiotic treatment of the most critically ill infants aged 0-59 days with suspected sepsis, meningitis and pneumonia.  The recommendations are intended for a wide"
    },
    {
        "doc_id": "doc_4",
        "chunk_num": 1,
        "chunk_text": "audience involved in the management of serious bacterial infections in infants aged 0-59 days. Web annex:\u00a0 Web Annex. Evidence base. GRADE tables. Available at:\u00a0Download link"
    },
    {
        "doc_id": "doc_5",
        "chunk_num": 0,
        "chunk_text": "The WHO guidelines for malaria bring together the Organization\u2019s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform.  The WHO guidelines for malaria bring together the Organization\u2019s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform. The Guidelines supersedes 2 previous WHO publications: the Guidelines for the treatment of malaria, third edition and the Guidelines for malaria vector control."
    },
    {
        "doc_id": "doc_5",
        "chunk_num": 1,
        "chunk_text": "Recommendations on malaria will continue to be reviewed and, where appropriate, updated based on the latest available evidence. Any updated recommendations will always display the date of the most recent revision in the MAGICapp platform. With each update, a new PDF version of the consolidated guidelines will also be available for download on the WHO website. This version of the Guidelines includes an updated recommendation for malaria vaccines, new recommendations on the use of near-patients"
    },
    {
        "doc_id": "doc_5",
        "chunk_num": 2,
        "chunk_text": "qualitative and semiquantitative G6PD tests to guide anti-relapse treatment of P. vivax and P. ovale, updated recommendations on primaquine and the recommendation on the use of tafenoquine. It replaces the versions published on 16 February 2021, 13 July 2021, 18 February 2022, 31 March 2022, 3 June 2022, 25 November 2022, 14 March 2023 and 16 October 2023. The guidelines are also available in Arabic, French and Spanish\u00a0on MAGICapp.\u00a0 \u2192\u00a0Version updates to the \"WHO guidelines for malaria\""
    },
    {
        "doc_id": "doc_7",
        "chunk_num": 0,
        "chunk_text": "Rheumatic fever (RF) and Rheumatic heart disease (RHD) are a preventable public health problem in low- and middle-income countries and in marginalized communities in middle- and high-income countries. RF is an autoimmune inflammatory reaction to throat infections (pharyngitis) or possibly to superficial skin and skin structure infections caused by Streptococcus pyogenes, a group A beta\u2010haemolytic Streptococcus (GAS) bacterium. The first episode of RF is commonly seen in children aged 5 to 14"
    },
    {
        "doc_id": "doc_7",
        "chunk_num": 1,
        "chunk_text": "years. Recurrent episodes are most common within 1 year of the first episode but can occur throughout the life course. RHD is characterized by chronic structural and/or functional changes in the heart, most commonly in the valves, caused by one or more episodes of rheumatic fever (RF). RHD most commonly starts in childhood with a diagnostic peak in young adults\u00a0 aged 20 to 39 years. RHD can lead to death or lifelong disability, however, effective early intervention can prevent premature"
    },
    {
        "doc_id": "doc_7",
        "chunk_num": 2,
        "chunk_text": "morbidity and mortality. The WHO guideline on the prevention and diagnosis of rheumatic fever (RF) and rheumatic heart disease (RHD) provides evidence-informed recommendations for the prevention and management of RF and RHD. It encompasses three areas; 1) primary prevention of rheumatic fever and rheumatic heart disease, specifically the identification and treatment of suspected group A (beta-haemolytic) Streptococcus (GAS) pharyngitis and skin infections; 2) secondary prevention of recurrent"
    },
    {
        "doc_id": "doc_7",
        "chunk_num": 3,
        "chunk_text": "rheumatic fever and of rheumatic heart disease, specifically use of long-term antibiotic prophylaxis, interventions to increase adherence to antibiotic prophylaxis, and screening for early rheumatic heart disease; and 3) management of rheumatic fever, specifically the treatment with anti-inflammatory drugs.  The recommendations are intended for wide audience involved in the prevention and management of RF and RHD. \u00a0 \u00a0 Web Annexes Web annex A: The processes, methods, and key questions Web annex"
    },
    {
        "doc_id": "doc_7",
        "chunk_num": 4,
        "chunk_text": "B: Unpublished systematic review reports"
    }
]